Category: News & Events

Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Heart failure is an end stage cardiac disease that has been associated with high mortality and rehospitalization rates in previous decades, in spite of standard anti-heart failure therapy, thus posing a major social and economic burden on public health.

Several studies have demonstrated that sodium-glucose cotransporter 2 inhibitors (SGLT2i), anti-hyperglycemic drugs whose function is independent of islet function, have significant positive effects on prognosis and quality of life, by decreasing mortality and readmission rates in patients with heart failure.

To increase general clinicians’ understanding and facilitate the practical application of SGLT2i in the treatment of heart failure, the mechanisms through which SGLT2i alleviate heart failure are reviewed in this article.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0028

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiangjun Wei and Jianlin Du. Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0028

Loading

Incidence, Predictors and Associations Between In-Hospital Bleeding and Adverse Events in Patients with Acute Coronary Syndrome Above 75 Years of Age

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Bleeding events in patients with acute coronary syndrome (ACS) are associated with poor outcomes. Risk factors and their associations with in-hospital events in older patients with ACS are not fully understood, because older patients with ACS are often excluded from randomized controlled studies.

The authors of this article enrolled 962 patients with ACS above 75 years of age treated at a center between January 2012 and December 2016. The incidence and risk factors for in-hospital bleeding events, as well as their associations with in-hospital adverse events were evaluated.

Bleeding complications were observed in 38 patients (4.1%). The most common bleeding site was the gastrointestinal tract (52.6%). Anemia (P=0.007), renal insufficiency (P=0.019), use of positive inotropic medicines (P=0.006) and elevated leukocyte count (P=0.046) were independent predictors of in-hospital bleeding after adjustment for age, sex, atrial fibrillation history and hypertension history. In-hospital mortality (28.9% vs. 2.4%, P<0.001), stroke (5.3% vs. 0.5%, P<0.001) and the prevalence of heart failure (39.5% vs. 16.3%, P<0.001) were significantly higher in patients with than without bleeding.

The incidence of in-hospital bleeding was 4.1% in patients with ACS above 75 years of age in this cohort. Independent risk factors for in-hospital bleeding events included anemia, renal insufficiency and elevated leucocyte count. Bleeding events were strongly associated with in-hospital adverse events.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0029

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Cheng Wei, Zhaowei Zhu and Xinqun Hu et al. Incidence, Predictors and Associations Between In-Hospital Bleeding and Adverse Events in Patients with Acute Coronary Syndrome Above 75 Years of Age – The Real-World Scenario. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0029

Loading

Single-Cell RNA Sequencing Maps Immune Cell Heterogeneity in Mice with Allogeneic Cardiac Transplantation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Immune cells play important roles in mediating allograft rejection and tolerance after cardiac transplantation. However, immune cell heterogeneity at the single-cell level, and how immune cell states shape transplantation immunity, remain incompletely characterized.

The authors of this article performed single-cell RNA sequencing (scRNA-seq) on immune cells in LNs from a mouse syngeneic and allogeneic cardiac transplantation model. Nine T cell clusters were identified through unsupervised analysis. Pathway enrichment analysis was used to explore the functional differences among cell subpopulations and to characterize the metabolic heterogeneity of T cells.

The transcriptional landscape of immune cells was determined, particularly T cells, and their metabolic transcriptomes in LNs during mouse cardiac transplantation. On the basis of molecular and functional properties, we also identified T cell types associated with transplantation-associated immune processes, including cytotoxic CD8+ T cells, activated conventional CD4+ T cells, and dysfunctional Tregs. The contribution of JunB to the induction of Th17 cell differentiation and restriction of Treg development was further elucidated, and the authors identified that HIF-1a participates in T cell metabolism and function.

The first systematic single-cell analysis of transcriptional variation within the T cell population is presented in this article, providing new insights for the development of novel therapeutic targets for allograft rejection.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0023

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhonghua Tong, Ge Mang and Dongni Wang et al. Single-Cell RNA Sequencing Maps Immune Cell Heterogeneity in Mice with Allogeneic Cardiac Transplantation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0023

Loading

Comparison of the Safety and Efficacy of Warfarin Versus Rivaroxaban in Northern Chinese Patients with Different CHA2DS2-VASc Scores

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   This study was aimed at evaluating the safety and efficacy of warfarin versus rivaroxaban in patients with atrial fibrillation (AF) and different CHA2DS2-VASc score subgroups in northern China.

A retrospective cohort study was conducted to evaluate 387 patients with AF who received treatment at an institution between September 2018 and August 2019. The patients were divided into two groups receiving either warfarin (n=194) or rivaroxaban (n=193). Follow-up data were collected, including adherence, bleeding and ischemic stroke events.

The group receiving rivaroxaban showed better adherence than the group receiving warfarin. In the warfarin-treated group, bleeding incidents declined with increasing scores. In the warfarin-treated group, patients with scores of 2–3 had greater adherence and fewer stroke occurrences. The events of bleeding and stroke did not significantly differ in patients in the rivaroxaban-treated group with different scores.

Compared with patients in the warfarin group with different CHA2DS2-VASc scores, those in the rivaroxaban group had greater compliance, and fewer bleeding and stroke events. Regardless of economic considerations, rivaroxaban is preferable for anticoagulative AF treatment in northern Chinese patients.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0030

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Shiwei Xu, Qi Zhao and Haiyu Zhang et al. Comparison of the Safety and Efficacy of Warfarin Versus Rivaroxaban in Northern Chinese Patients with Different CHA2DS2-VASc Scores: A Retrospective Cohort Study. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0030

Loading

Coronavirus Disease 2019, Myocardial Injury, and Myocarditis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. After its initial outbreak in 2019, the 2019 novel coronavirus disease (COVID-19) remains a global health concern. COVID-19 is well known for causing severe respiratory pathology, but it can also cause a variety of extra-pulmonary manifestations. Among them, myocardial injury has received substantial attention because it is usually associated with poor prognosis and mortality, thus emphasizing the importance of monitoring and managing myocardial injury in patients with COVID-19. Myocarditis has received attention as a complication of myocardial injury during and after the onset of COVID-19. Here, to aid in clinical decision-making, the authors of this article present a narrative review on COVID-19- associated myocardial injury and myocarditis, discussing clinical evidence, pathogenesis, diagnostic tools, and therapeutic strategies.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0025

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Lilin Xiang, Lin Zhang and Tong Zhang et al. Coronavirus Disease 2019, Myocardial Injury, and Myocarditis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0025

Loading

Predictive Value of a Combination of the Age, Creatinine and Ejection Fraction (ACEF) Score and Fibrinogen Level in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The purpose of this study was to explore whether consideration of FIB levels might improve the predictive value of the ACEF score in patients with ACS.

A total of 290 patients with ACS were enrolled in this study. The clinical characteristics and MACE were recorded. Multivariate logistic regression analysis revealed that the FIB level (odds ratio=7.798, 95%CI, 3.44–17.676, P<0.001) and SYNTAX score (odds ratio=1.034, 95%CI, 1.001–1.069, P=0.041) were independent predictors of MACE. On the basis of the regression coefficient for FIB, the ACEF-FIB was developed. The area under the ROC of the ACEF-FIB scoring system in predicting MACE after PCI was 0.753 (95%CI 0.688–0.817, P<0.001), a value greater than those for the ACEF score, SYNTAX score and Grace score (0.627, 0.637 and 0.570, respectively).

ACEF-FIB had better discrimination ability than the other risk scores, according to ROC curve analysis, net reclassification improvement and integrated discrimination improvement.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0027

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yuhao Zhao, Zongsheng Guo and Zheng Liu et al. Predictive Value of a Combination of the Age, Creatinine and Ejection Fraction (ACEF) Score and Fibrinogen Level in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0027

Loading

Artificial Intelligence Solutions for Cardiovascular Disease Detection and Management in Women

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Artificial intelligence (AI) is a method of data analysis that enables machines to learn patterns from datasets and make predictions. With advances in computer chip technology for data processing and the increasing availability of big data, AI can be leveraged to improve cardiovascular care for women – an often understudied and undertreated population. The authors of this article briefly discuss the potential benefits of AI-based solutions in cardiovascular care for women and also highlight inadvertent drawbacks to the use of AI and novel digital technologies in women.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0024

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Wendy Tatiana Garzon-Siatoya, Andrea Carolina Morales-Lara and Demilade Adedinsewo. Artificial Intelligence Solutions for Cardiovascular Disease Detection and Management in Women: Promise and Perils. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0024

Loading

Angiography-Derived Fractional Flow Reserve in Coronary Assessment: Current Developments and Future Perspectives

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Coronary physiology assessment is an important factor in guiding myocardial revascularization. A growing body of research highlights the value of using fractional flow reserve, FFR and other pressure-based indicators for functional assessment of stable coronary stenoses. Invasive functional coronary assessment techniques have evolved from intracoronary wire-based to wire-free approaches as a result of technological advancements. In addition, several software programs on the market have been thoroughly investigated and validated against invasive FFR, and have shown good accuracy and correlation. However, use of FFR remains modest.

This article provides an overview of angiography-based FFR solutions and compares their technologies. Additionally, a systematic scoping review was performed to understand the research landscape in wire-free coronary physiology assessment, to complement the narratives of existing FFR trials on wire-free FFR. Furthermore, future developments and strategies that could expand the use of wire-free computed coronary functional assessment in the Asia Pacific region are discussed.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0021

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Han Bing Chow, Shirley Siang Ning Tan and Wei Hong Lai et al. Angiography-Derived Fractional Flow Reserve in Coronary Assessment: Current Developments and Future Perspectives. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0021

Loading

Integration Analysis of Epigenetic-related m 6A-SNPs Associated with Atrial Fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Numerous single nucleotide polymorphisms (SNPs) have been identified as genetic contributors to atrial fibrillation (AF). The aim of this study was to investigate the effects of genome-wide N6-methyladenosine (m6A)-SNPs on AF.

m6A-SNPs were identified by analysis of raw data from published AF GWAS datasets and the list of m6A-SNPs from the m6AVar database. Expression quantitative trait loci (eQTL) analysis was conducted to evaluate the effects of m6A-SNPs on gene expression. The expression of linked genes was validated in three independent AF-associated gene expression datasets (GSE14975, GSE108660 and GSE2240).

A total of 1429 (6.2%) unique m6A-SNPs that were significantly associated with AF were identified. Seventeen m6A-SNPs in 14 genes reached genome-wide significance. Eight m6A-SNPs demonstrated eQTL signals. Four m6A-SNPs (rs383692, rs3211105, rs1061259 and rs1152582) exhibited strong cis-eQTL signals associated with the gene expression levels of SMIM8, JMJD1C and SYNE2. SYNE2 and SMIM8 had differential gene expression levels between the AF and sinus rhythm groups. In addition, SYNE2 expression was uniformly downregulated in AF samples compared with normal control samples in the three datasets.

The results provide the first demonstration that m6A-SNPs are strongly associated with AF, and extend understanding of m6A modification as a potential biological pathway underlying AF.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0022

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Zhenhong Jiang, Xin Liu and Jianping Hu et al. Integration Analysis of Epigenetic-related m6A-SNPs Associated with Atrial Fibrillation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0022

Loading

Inhibition of Stimulator of Interferon Genes Protects Against Myocardial Ischemia-Reperfusion Injury in Diabetic Mice

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Although the past decade has witnessed substantial scientific progress with the advent of cardioprotective pharmacological agents, most have failed to protect against myocardial ischemia/reperfusion (I/R) injury in diabetic hearts. This article investigates the role of stimulator of interferon genes (STING) in I/R injury in diabetic mice and further exploring the underlying mechanisms.

Type 2 diabetic mice were subjected to I/R or sham operation to investigate the role of STING. STING knockout mice were subjected to 30 minutes of ischemia followed by reperfusion for 24 hours. Finally, myocardial injury, cardiac function, and inflammation levels were assessed.

STING pathway activation was observed in diabetic I/R hearts, as evidenced by increased p-TBK and p-IRF3 expression. STING knockout significantly decreased the ischemic area and improved cardiac function after I/R in diabetic mice. STING knockout also elicited cardio-protective effects by decreasing serum cardiac troponin T and lactate dehydrogenase levels, thus diminishing the inflammatory response in the heart after I/R in diabetic mice. In vitro, STING inhibition decreased the expression of hypoxia-re-oxygenation-induced inflammatory cytokines.

Targeting STING inhibits inflammation and prevents I/R injury in diabetic mice. Thus, STING may be a potential novel therapeutic target against myocardial I/R injury in diabetes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0020

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yuce Peng, Guoxiang Zhou and Mingyu Guo et al. Inhibition of Stimulator of Interferon Genes Protects Against Myocardial Ischemia-Reperfusion Injury in Diabetic Mice. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0020

Loading